ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

NavnABBVON

RangeringNo.3150

Markedsverdi$0.00

Fullt utvannet markedsverdi$0.00

Markedsandel%

Handelsvolum/markedsgrense (24 timer)426,994.90%

Opplagsforsyning215.74112722

Maksimal forsyning0

Total forsyning215.74112722

Opplagsforsyning%

Utstedelsesdato--

Prisen for aktivaen da den først ble utstedt--

All-time high237.64005999136555,2026-03-05

Laveste pris203.8145967524712,2026-03-24

Offentlig blokkjedeETH

IntroduksjonAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Sektor

Sosiale medier

• Offisiell nettside
• Blokker Explorer

etfindex:mc_etfindex_sourceAnsvarsfraskrivelse: Dataene leveres av cmc og bør ikke betraktes som investeringsråd.